- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02528526
Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm (OXY1A)
A Phase IB/IIA, Single-centered Study of the Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasia
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
The IMP OXY111A counteracts hypoxia-induced tumor aggressiveness showing decreased tumor burden and increased survival in five different animal solid tumor models both applied as monotherapy and increased beneficial effects when followed by standard chemotherapy. The unique ability of the IMP counteract hypoxic tumor behaviour along with its non-toxic side effects tested both in animals and healthy volunteers is of outmost interest to explore in patients with solid tumors.
The study seeks primarily to determine the safety and tolerability of OXY111A in patients with primary and secondary hepato-pancreato-biliary and gastrointestinal neoplasia as measured by exploring the MTD in a conservative 3+3 dose escalation schedule. The window for DLT assessment is from first dose of study drug until first dose of standard of care chemotherapy or 10 days following completion of last dose of study drug (whichever is shorter in duration). Additionally, we will assess efficacy of OXY111A on decreasing tumor volume, metabolic activity, as well as circulatory tumor and angiogenic markers.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Pierre-Alain Clavien, MD, PhD
- Telefonnummer: +41 (0)44 255 33 00
- E-post: clavien@access.uzh.ch
Studera Kontakt Backup
- Namn: Perparim Limani, MD
- Telefonnummer: +41 (0)44 255 33 00
- E-post: perparim.limani@usz.ch
Studieorter
-
-
ZH
-
Zurich, ZH, Schweiz, 8091
- Rekrytering
- University Hospital Zurich, Visceral surgery
-
Kontakt:
- Pierre-Alain Clavien, MD, PhD
- Telefonnummer: +41 (0)44 255 33 00
- E-post: clavien@access.uzh.ch
-
Kontakt:
- Perparim Limani, MD
- Telefonnummer: +41 (0)44 255 33 00
- E-post: perparim.limani@usz.ch
-
Underutredare:
- Panagiotis Samaras, MD
-
Underutredare:
- Bernhard Pestalozzi, MD
-
Underutredare:
- Alexander Jetter, MD
-
Underutredare:
- Michael Linecker, MD
-
Underutredare:
- Rolf Graf, PhD
-
Underutredare:
- Bostjan Humar, PhD
-
Underutredare:
- Henrik Petrowsky, MD
-
Underutredare:
- Philipp Kron, MD
-
Underutredare:
- Roger Stupp, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Study Indication: patients diagnosed for non-resectable hepato-pancreato-biliary or gastrointestinal neoplasm
- Male and Female patients ≥ 18 years of age
- Signed Informed Consent after being informed
- Eastern Cooperative Oncology Group (ECOG) performance status score of ≥ 2 at study entry.
- A life-expectancy of >3 months
- Adequate hematologic and renal function
- Use of effective contraception (per the institutional standard), if procreative potential exists
- Adequate recovery from recent surgery, chemotherapy, and radiation therapy. At least 28 days must have elapsed from major surgery, prior chemotherapy, prior treatment with an investigational agent or device, or prior radiation therapy (palliative radiation therapy is allowed)
- Accessible for treatment and follow-up. Patients enrolled in this trial must be treated at the participating center
Exclusion Criteria:
- Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product
- Women who are pregnant or breast feeding
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Treatment
Add-on application of Myo-inositol trispyrophosphate, total of 9 times, 3 applications per week, over 3 weeks.
|
OXY111A intravenous infusion
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Safety and tolerability as measured by collection of adverse effects information
Tidsram: 10 weeks
|
Safety variables and patient tolerance as measured by collection of adverse effects information according to Common Terminology Criteria for Adverse Events (CTCAE)
|
10 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Efficacy as measured by FDG-PET scan
Tidsram: 5 months
|
Assessment of tumor response with 18F-FDG PET in FDG-avid tumors using EORTC criteria
|
5 months
|
Efficacy as measured by MRI
Tidsram: 5 months
|
Assessment of tumor response with MRI in non-FDG-avid tumors using RECIST criteria
|
5 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Pierre Alain, Clavien, University Hospital Zurich, Visceral surgery
Publikationer och användbara länkar
Allmänna publikationer
- Aprahamian M, Bour G, Akladios CY, Fylaktakidou K, Greferath R, Soler L, Marescaux J, Egly JM, Lehn JM, Nicolau C. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1alpha suppression and eradication of early hepatoma tumors in rats. Chembiochem. 2011 Mar 21;12(5):777-83. doi: 10.1002/cbic.201000619. Epub 2011 Mar 2.
- Derbal-Wolfrom L, Pencreach E, Saandi T, Aprahamian M, Martin E, Greferath R, Tufa E, Choquet P, Lehn JM, Nicolau C, Duluc I, Freund JN. Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2. Oncogene. 2013 Sep 5;32(36):4313-8. doi: 10.1038/onc.2012.445. Epub 2012 Oct 8.
- Kieda C, El Hafny-Rahbi B, Collet G, Lamerant-Fayel N, Grillon C, Guichard A, Dulak J, Jozkowicz A, Kotlinowski J, Fylaktakidou KC, Vidal A, Auzeloux P, Miot-Noirault E, Beloeil JC, Lehn JM, Nicolau C. Stable tumor vessel normalization with pO(2) increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. J Mol Med (Berl). 2013 Jul;91(7):883-99. doi: 10.1007/s00109-013-0992-6. Epub 2013 Mar 9.
- Raykov Z, Grekova SP, Bour G, Lehn JM, Giese NA, Nicolau C, Aprahamian M. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J Cancer. 2014 Jun 1;134(11):2572-82. doi: 10.1002/ijc.28597. Epub 2013 Nov 25.
- Fylaktakidou KC, Lehn JM, Greferath R, Nicolau C. Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1605-8. doi: 10.1016/j.bmcl.2005.01.064.
- Schneider MA, Linecker M, Fritsch R, Muehlematter UJ, Stocker D, Pestalozzi B, Samaras P, Jetter A, Kron P, Petrowsky H, Nicolau C, Lehn JM, Humar B, Graf R, Clavien PA, Limani P. Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors. Nat Commun. 2021 Jun 21;12(1):3807. doi: 10.1038/s41467-021-24069-w.
- Limani P, Linecker M, Kron P, Samaras P, Pestalozzi B, Stupp R, Jetter A, Dutkowski P, Mullhaupt B, Schlegel A, Nicolau C, Lehn JM, Petrowsky H, Humar B, Graf R, Clavien PA. Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial. BMC Cancer. 2016 Oct 19;16(1):812. doi: 10.1186/s12885-016-2855-3.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer efter plats
- Adenocarcinom
- Carcinom
- Neoplasmer, körtel och epitel
- Sjukdomar i det endokrina systemet
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Gastrointestinala sjukdomar
- Neoplasmer i endokrina körtel
- Leversjukdomar
- Kolonsjukdomar
- Tarmsjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Bukspottkörtelsjukdomar
- Neoplasmer
- Karcinom, hepatocellulärt
- Kolorektala neoplasmer
- Pankreatiska neoplasmer
- Kolangiokarcinom
- Neoplasmer i levern
- Läkemedels fysiologiska effekter
- Mikronäringsämnen
- Vitaminer
- Vitamin B-komplex
- Inositol
Andra studie-ID-nummer
- OXY1A_2014-0374
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kolorektala neoplasmer
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Ooperbar malign neoplasm | Avancerad malign neoplasmFörenta staterna
-
Massachusetts General HospitalRekryteringMalign neoplasm | Benign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMalign neoplasm | Metastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeTrötthet | Metastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasmFörenta staterna
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)AvslutadAvancerad malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasm | BRAF genmutationFörenta staterna
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityTillgängligtMalign neoplasm | Hematopoetisk celltransplantationsmottagare | Benign neoplasm | Mottagare för benmärgstransplantationFörenta staterna